Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Mansilla-Olivares.
El calcio, átomo detonante de la vida y la función celular.
Cir Ciruj, 72 (2004), pp. 139-151
[2.]
E. Carafoli.
Calcium signaling: a tale for all seasons.
Proc Natl Acad Sci USA, 99 (2002), pp. 1115-1122
[3.]
W.E. Stumpf, M. Sar, F.A. Reid, Y. Tanaka, H.F. DeLuca.
Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid.
Science, 206 (1979), pp. 1188-1190
[4.]
S.C. Manolagas, D.M. Provvedini, C.D. Tsoukas.
Interactions of 1,25-dihydroxy vitamin D3 and the inmune system.
Mol Cell Endocrinol, 43 (1985), pp. 113-122
[5.]
C. Mathieu, L. Adorini.
The coming of age of 1,25-dihyydroxyvitamin D3 analogs as inmunomodulatory agents.
Trends Mol Med, 8 (2002), pp. 174-179
[6.]
D. Matusiak, G. Murillo, R.E. Carroll, R.G. Mehta, R.V. Benya.
Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon.
Cancer Epidemiol Biomarkers Prev, 14 (2005), pp. 2370-2376
[7.]
R. Bland, D. Zehnder, M. Hewison.
Expression of 25-hydroxyvitamin D3-1alpha –hidroxylase along the nephron: new insights into renal vitamin D metabolism.
Curr Opin Nephrol Hypertens, 9 (2000), pp. 17-22
[8.]
J.L. Omdahl, E.A. Bobrovnikova, S. Choe, P.P. Dwivedi, B.K. May.
Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway.
Steroids, 66 (2001), pp. 381-389
[9.]
G. Penna, L. Adorini.
1 Alfa,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation.
J Immunol, 164 (2000), pp. 2405-2411
[10.]
V. Tangpricha, J.N. Flanagan, L.W. Whitlatch, C.C. Tseng, T.C. Chen, P.R. Holt, et al.
25-hydroxyvitamin D-1α–hydroxylase in normal amb malignant colon tissue.
Lancet, 357 (2001), pp. 1673-1674
[11.]
E.B. Mawer, M.E. Hayes, S.E. Heys, M. Davies, A. White, M.F. Stewart, et al.
Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cell line.
J Clin Endocrinol Metab, 79 (1994), pp. 554-560
[12.]
P. Mezquita-Raya, M. Muñoz-Torres, J.D. Luna, V. Luna, F. López-Rodríguez, E. Torres-Vela.
Relation between vitamin D insufficiency, bone density and bone metabolism in healthy postmenopausal women.
J Bone Miner Res, 16 (2001), pp. 1408-1415
[13.]
M. Moreno, E. Casado, M. Larrosa, A. Gómez, J. Gratacós.
Factors related with severity of hip fracture.
Arthritis Rheum, 54 (2006), pp. S82
[14.]
M.S. Stein, J.D. Wark, S.C. Scherer, S.L. Walton, P. Chick, M. Di Carlantonio, et al.
Falls relate to vitamin D and parathyroid hormone in an Australian nursing home and hostel.
J Am Geriatr Soc, 47 (1999), pp. 1195-1201
[15.]
P. Aguado, M.V. Garcés, M.L. González Casaus, M.T. Del Campo, P. Richi, J. Coya, et al.
Alta prevalencia de deficiencia de vitamina D en mujeres posmenopáusicas de una consulta reumatológica en Madrid. Evaluación de dos pautas de prescripción de vitamina D.
Med Clin (Barc), 114 (2000), pp. 326-330
[16.]
J.M. Quesada, I. Jans, P. Benito, J.A. Jiménez, R. Bouillon.
Vitamin D status of elderly people in Spain.
Age Ageing, 18 (1989), pp. 392-397
[17.]
D. Yeste, A. Carrascosa.
Raquitismo carencial en la infancia: análisis de 62 casos.
Med Clin (Barc), 121 (2003), pp. 23-27
[18.]
M. Larrosa, J. Gratacòs, M. Vaqueiro, M. Prat, F. Campos, M. Roque.
Prevalencia de hipovitaminosis D en una población anciana institucionalizada. Valoración del tratamiento sustitutivo.
Med Clin (Barc), 117 (2001), pp. 611-614
[19.]
Larrosa M, Gómez A, Moreno M, Casado E, Berlanga E, Ramón J, et al. Déficit de vitamina D en la fractura osteoporótica de cadera y factores asocionados [en prensa]. Med Clin (Barc).
[20.]
M. Peterlik, H.S. Cross.
Dysfunction of the vitamin D endocrine system as common cause for multiple malignant and other chronic diseases.
Anticancer Res, 26 (2006), pp. 2581-2588
[21.]
M.T. Cantorna, C. Munsick, C. Bemiss, B.D. Mahon.
1,25-Dihydroxy cholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease.
J Nutr, 130 (2000), pp. 2648-2650
[22.]
M.T. Cantorna, C.E. Hayes, H.F. DeLuca.
1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis.
Proc Natl Acad Sci U S A, 93 (1996), pp. 7861-7864
[23.]
C. Mathieu, M. Waer, J. Laureys, O. Rutgeerts, R. Bouillon.
Prevention of autoinmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3.
Diabetologia, 37 (1994), pp. 552-558
[24.]
M.T. Cantorna, C.E. Hayes, H.F. DeLuca.
1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis.
J Nutr, 128 (1998), pp. 68-72
[25.]
L.A. Merlino, J. Curtis, T.R. Mikuls, J.R. Cerhan, L.A. Criswell, K.G. Saag, Iowa Women's Health Study.
Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study.
Arthritis Rheum, 50 (2004), pp. 72-77
[26.]
K.L. Munger, S.M. Zhang, E. O’Reilly, M.A. Hernan, M.J. Olek, W.C. Willett, et al.
Vitamin D intake and incidence of multiple sclerosis.
Neurology, 62 (2004), pp. 60-65
[27.]
C.F. Garland, E.D. Gorham, S.B. Mohr, W.B. Grant, E.L. Giovannucci, M. Lipkin, et al.
Vitamin D and prevention of breast cancer: pooled analysis.
J Steroid Biochem, 103 (2006), pp. 708-711
[28.]
C.F. Garland, F.C. Garland, E.D. Gorham, M. Lipkin, H. Newmark, S.B. Mohr, et al.
The role of vitamin D in cancer prevention.
Am J Public Health, 96 (2006), pp. 252-261
[29.]
H.G. Skinner, D.S. Michaud, E. Giovannucci, W.C. Willett, G.A. Colditz, C.S. Fuchs.
Vitamin D intake and the risk for pancreatic cancer in two cohort studies.
Cancer Epidemiol Biomarkers Prev, 15 (2006), pp. 1688-1695
[30.]
W.B. Grant.
An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking.
Int J Cancer, 120 (2007), pp. 1123-1128
[31.]
C. Palmieri, T. MacGregor, S. Girgis, D. Vigushin.
Serum 25-hydroxy vitamin D levels in early and advanced breast cancer.
J Clin Pathol, 59 (2006), pp. 1334-1336
[32.]
A.C. Porojnicu, T.E. Robsahm, A. Dahlback, J.P. Berg, D. Christiani, O.S. Bruland, Seasonal and geographical variations in lung cancer prognosis in Norway., et al.
Does vitamin D from the sun play a role?.
Lung Cancer, 55 (2007), pp. 263-270
[33.]
W.B. Grant.
The likely role of vitamin D from solar ultraviolet-B irradiance in increasing cancer survival.
Anticancer Res, 26 (2006), pp. 2605-2614
[34.]
A.J. Bronw.
Therapeutic uses of vitamin D analogues.
Am J Kindney Dis, 38 (2001), pp. S3-S19
[35.]
K. Kragballe, H.I. Beck, H. Sogaard.
Improvement of psoriasis by a topical vitamin D3 analogue (MC903) in a double-blind study.
Br J Dermatol, 119 (1988), pp. 223-230
[36.]
Documento de Consenso 2006 de la Sociedad Española de Reumatología sobre la osteoporosis posmenopáusica.
Panel de expertos del Documento de Consenso 2006 de la SER sobre la osteoporosis posmenopáusica.
Reumatol Clin, 3 (2007), pp. 26-32
[37.]
C. Gómez-Alonso, M.L. Naves-Díaz, J.L. Fernández-Martín, J.B. Díaz-López, M.T. Fernández-Coto, J.B. Cannata-Andia.
Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxivitamin D cut-off levels.
Kidney Int, 85 (2003), pp. S44-S48
[38.]
P. Lips, T. Duong, A. Oleksik, D. Black, S. Cummings, D. Cox, et al.
A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trials.
J Clin Endocrinol Metab, 86 (2001), pp. 1212-1221
[39.]
S.R. Mastaglia, C.A. Mautalen, M.S. Parisi, B. Oliveri.
Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women.
Eur J Clin Nutr, 60 (2006), pp. 681-687
[40.]
Larrosa M, Casado E, Gómez A, Moreno M, Berlanga E, Galisteo C, et al. Colecalciferol o calcidiol. Qué metabolito utilizar en el déficit de vitamina D[en prensa]. REEMO.
Copyright © 2007. Elsevier España S.L Barcelona
